ClinicalTrials.gg
CompletedNCT04343651Updated Jan 4, 2023Results posted

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

A Phase 2 interventional study of Placebo and Leronlimab (700mg) in Coronavirus Disease 2019, sponsored by CytoDyn, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-01-04.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
672nd of 1,321
86 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
64th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 672nd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 64th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.

Read the detailed description

This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.

The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.

A total of 75 subjects will be randomized 2:1 in this study.

03

Conditions studied

  • Coronavirus Disease 2019

Browse trials for

Keywords

  • COVID-19
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult ≥ 18 years of age at time of enrollment.
  2. Subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection as defined below:

    Mild (uncomplicated) Illness:

    • Diagnosed with COVID-19 by a standardized RT-PCR assay AND
    • Mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath AND
    • No signs of a more serious lower airway disease AND
    • RR\<20, HR \<90, oxygen saturation (pulse oximetry) > 93% on room air

    Moderate Illness:

    • Diagnosed with COVID-19 by a standardized RT-PCR assay AND
    • In addition to symptoms above, more significant lower respiratory symptoms, including shortness of breath (at rest or with exertion) OR
    • Signs of moderate pneumonia, including RR ≥ 20 but \<30, HR ≥ 90 but less than 125, oxygen saturation (pulse oximetry) > 93% on room air AND
    • If available, lung infiltrates based on X-ray or CT scan \< 50% present
  3. Clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator.
  4. Subject (or legally authorized representative) provides written prior to initiation of any study procedures.
  5. Understands and agrees to comply with planned study procedures.
  6. Women of must agree to use at least one medically accepted method of (e.g., barrier contraceptives [condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or intrauterine devices) for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects showing signs of acute respiratory distress syndrome (ARDS) or respiratory failure necessitating mechanical ventilation at the time of screening;
  2. History of severe chronic respiratory disease and requirement for long-term oxygen therapy;
  3. Subjects showing signs of clinical jaundice at the time of screening;
  4. History of moderate and severe liver disease ( score >12);
  5. Subjects requiring Renal Replacement Therapy (RRT) at the time of screening;
  6. History of severe chronic kidney disease or requiring dialysis;
  7. Any uncontrolled active systemic infection requiring admission to an intensive care unit (ICU); Note: Subjects infected with chronic virus or virus will be eligible for the study if they have no signs of hepatic decompensation.

    Note: Subjects infected with -1 will be eligible for the study with undetectable viral load and are on a stable ART regimen. Investigators are required to review the subjects' medical records to confirm HIV-1 RNA suppression within the previous 3 months.

    Note: Empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study.

  8. Patients with malignant tumor, or other serious systemic diseases;
  9. Patients who are participating in other clinical trials;
  10. Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible; and
  11. Inability to provide or to comply with test requirements
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    The placebo comparator consists of the formulation buffer for leronlimab, i.e., the placebo is the same as the active arm without leronimab. The placebo is presented in the same container closure at the same fill volume as the active (nominal 1mL fill volume). The formulation buffer contains histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.

    Drug: Placebo

  • Experimental
    700mg Leronlimab

    Each vial of active contains 175mg of leronlimab at a concentration of 175mg/ml (nominal 1mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.

    Drug: Leronlimab (700mg)

Interventions

  • DrugPlacebo

    Placebo

  • Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

    Also known as: PRO 140

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Total Symptom Score

    Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough) by count of patients showing improvement, no change or worsened. Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3. \[0=none, 1=mild, 2=moderate, and 3=severe\]. Higher scores mean a worse outcome. A negative change from baseline shows an improvement in symptom score.

    Time frame: Clinical Improvement will be assessed at baseline and at EOT (day 14).

Secondary outcomes

  1. Time to Clinical Resolution (TTCR)

    Defined as the time from initiation of study treatment to the resolution of clinical symptoms (fever, myalgia, dyspnea, cough). Data presented how the number of days at which a certain percentage of patients achieve resolution of symptoms, i.e., 50% of patients on placebo saw resolution of symptoms in 15 days, and 15 days for patients on leronlimab. The hazard ratio was 0.781, 95% Confidence Interval 0.43, 1.41 and the p-value was 0.4138. TTCR is defined as the duration from date of first exposure to treatment to the first occurrence of total symptom score equals 0.

    Time frame: Time (in days) from initiation of study treatment until resolution of clinical symptoms (fever, myalgia, dyspnea and cough).

  2. Incidence of Hospitalization

    Number of patients requiring hospitalization

    Time frame: From visit 2 (day 0) through day 14 (in days)

  3. Duration (Days) of Hospitalization

    Duration of hospitalization in days

    Time frame: Total duration of hospitalization between visit 2 (day 0) in days and end of treatment

  4. Incidence of Mechanical Ventilation

    Incidence of mechanical ventilation supply

    Time frame: Total duration of mechanical ventilation since visit 2 (day 0) (days)

  5. Duration of Mechanical Ventilation Supply

    Duration (days) of mechanical ventilation supply

    Time frame: Duration of mechanical ventilation since visit 2 (day 0) (days

  6. Incidence of Oxygen Use

    Incidence of oxygen use over course of treatment

    Time frame: Use of oxygen since visit 2 (day 0) to end of treatment

  7. Duration of Oxygen Use

    Duration of oxygen use in days

    Time frame: Total duration of oxygen use since visit 2 (day 0) to EOT (day 14) (days)

  8. Mortality at Day 14

    Incidence of mortality at day 14

    Time frame: Mortality at EOT (day 14)

  9. Time to Return to Normal Activity

    Time to return to normal activity from initiation of study treatment defined as duration from date of first exposure to treatment to the first occurrence of ordinal scale equals "not hospitalized, no limitations of activities"

    Time frame: Date of first exposure to treatment to the first occurrence of ordinal scale equals "not hospitalized, no limitations of activities"

  10. Change From Baseline in National Early Warning Score 2 (NEWS2) to Day 3, 7 and 14

    NEWS2 is an assessment based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness) developed by the Royal College of Physicians (https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2). Respiratory rate (bpm) scores 0-3; Sp02 (on room air or suppl) scores 0-3; SpO2 (hypercapnic resp failure) scores 0-3; room air or supplemental O2 scores 0 (room) or 2 (suppl); temperature - scores 0-3; systolic BP scores 0-3; pulse (bpm) scores 0-3; consciousness - alert (score 0) vs. new onset confusion (score 3). The total possible score ranges from 0 to 20. The higher the score the greater the clinical risk. Higher scores indicate the need for escalation, medical review and possible clinical intervention and more intensive monitoring. Change shown is positive or negative from baseline, with a negative number indicating improvement (i.e., a decrease in total score).

    Time frame: Baseline to Day 3, 7 and 14

  11. Mean Change in Percent Oxygen Saturation From Baseline to Days 3, 7 and 14

    Mean change in percent oxygen saturation from baseline to Days 3, 7 and 14 for patients with paired values

    Time frame: Mean change in percent oxygen saturation from baseline to Days 3, 7 and 14

  12. Change From Baseline in the Patient's Health Status on a 7-category Ordinal Scale on Days 3, 7 and 14

    A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Lower scores mean a worse outcome.

    Time frame: Assessments performed Day 0 (first treatment is Visit 2, day 0), Visit 3 (3+/- 1 day after first treatment) Visit 4 (second treatment, 7+/- 1 day from V2, day7) and end of treatment (7+/- 1 day from V4, day 14)

Other outcomes

  1. Change in Size of Lesion Area by Chest Radiograph or CT

    Change in size of lesion area by chest radiograph or CT - exploratory endpoint

    Time frame: Day 14

  2. Change From Baseline in Serum Cytokine and Chemokine Levels

    Change from baseline in serum cytokine and chemokine levels at day 3, day 7 and day 14

    Time frame: Days 3, 7, and 14

  3. Change From Baseline in CCR5 Receptor Occupancy Levels for Tregs and Macrophages

    Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages at day3, day 7 and day 14

    Time frame: Days 3, 7, and 14

  4. Change From Baseline in CD3+, CD4+ and CD8+ T Cell Count

    Change from baseline in CD3+, CD4+ and CD8+ T cell count at day 3, day 7 and day 14

    Time frame: Days 3, 7, and 14

07

Results

Posted Jan 4, 2023

Participant flow

Participants were enrolled at study sites in the United States. The first participant was randomized on 30-Apr-2020. Data submitted represent analysis performed on data collected after all patients completed the Follow UP period.

Participant flow — Overall Study
MilestonePlacebo700mg Leronlimab
Started2957
Completed1733
Not completed1224
Withdrew: Physician decision21
Withdrew: Lost to follow-up21
Withdrew: Protocol violation46
Withdrew: Missing39
Withdrew: Withdrawal by subject04
Withdrew: Death01
Withdrew: Did not start treatment11
Withdrew: Patient did not complete visits 3-601

Outcome measures

PrimaryMean Change From Baseline in Total Symptom Score

Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough) by count of patients showing improvement, no change or worsened. Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3. \[0=none, 1=mild, 2=moderate, and 3=severe\]. Higher scores mean a worse outcome. A negative change from baseline shows an improvement in symptom score.

Time frame:
Clinical Improvement will be assessed at baseline and at EOT (day 14).
Reported as:
Mean · units on a scale
Mean Change From Baseline in Total Symptom Score
units on a scalePlacebo700mg Leronlimab
Mean Change From Baseline in Total Symptom Score-3.4 ± 3.19-3.5 ± 3.03
Statistical analysis
  • Placebo vs 700mg Leronlimab · ANCOVA · p = 0.818
SecondaryTime to Clinical Resolution (TTCR)

Defined as the time from initiation of study treatment to the resolution of clinical symptoms (fever, myalgia, dyspnea, cough). Data presented how the number of days at which a certain percentage of patients achieve resolution of symptoms, i.e., 50% of patients on placebo saw resolution of symptoms in 15 days, and 15 days for patients on leronlimab. The hazard ratio was 0.781, 95% Confidence Interval 0.43, 1.41 and the p-value was 0.4138. TTCR is defined as the duration from date of first exposure to treatment to the first occurrence of total symptom score equals 0.

Time frame:
Time (in days) from initiation of study treatment until resolution of clinical symptoms (fever, myalgia, dyspnea and cough).
Reported as:
Number · days
Time to Clinical Resolution (TTCR)
daysPlacebo700mg Leronlimab
25% subjects58
50% subjects1515
75% subjects1515
Statistical analysis
  • Placebo vs 700mg Leronlimab · Likelihood test-Cox Prop. hazards model · p = 0.4138 · Hazard ratio (hr): 0.781 · 95% CI 0.43 to 1.41Stratification factors: Baseline NEWS Total score and Age.
SecondaryIncidence of Hospitalization

Number of patients requiring hospitalization

Time frame:
From visit 2 (day 0) through day 14 (in days)
Reported as:
Number · participants
Incidence of Hospitalization
participantsPlacebo700mg Leronlimab
None1122
1 time1433
2 times31
SecondaryDuration (Days) of Hospitalization

Duration of hospitalization in days

Time frame:
Total duration of hospitalization between visit 2 (day 0) in days and end of treatment
Reported as:
Mean · days
Duration (Days) of Hospitalization
daysPlacebo700mg Leronlimab
Duration (Days) of Hospitalization2.0 ± 3.192.1 ± 3.83
SecondaryIncidence of Mechanical Ventilation

Incidence of mechanical ventilation supply

Time frame:
Total duration of mechanical ventilation since visit 2 (day 0) (days)
Reported as:
Count of participants · Participants
Incidence of Mechanical Ventilation
ParticipantsPlacebo700mg Leronlimab
None2755
1 Time11
SecondaryDuration of Mechanical Ventilation Supply

Duration (days) of mechanical ventilation supply

Time frame:
Duration of mechanical ventilation since visit 2 (day 0) (days
Reported as:
Mean · days
Duration of Mechanical Ventilation Supply
daysPlacebo700mg Leronlimab
Duration of Mechanical Ventilation Supply0.4 ± 1.960.2 ± 1.00
SecondaryIncidence of Oxygen Use

Incidence of oxygen use over course of treatment

Time frame:
Use of oxygen since visit 2 (day 0) to end of treatment
Reported as:
Count of participants · Participants
Incidence of Oxygen Use
ParticipantsPlacebo700mg Leronlimab
None2247
One time56
Two times12
Three times01
SecondaryDuration of Oxygen Use

Duration of oxygen use in days

Time frame:
Total duration of oxygen use since visit 2 (day 0) to EOT (day 14) (days)
Reported as:
Mean · days
Duration of Oxygen Use
daysPlacebo700mg Leronlimab
Duration of Oxygen Use0.8 ± 2.810.9 ± 2.98
SecondaryMortality at Day 14

Incidence of mortality at day 14

Time frame:
Mortality at EOT (day 14)
Reported as:
Count of participants · Participants
Mortality at Day 14
ParticipantsPlacebo700mg Leronlimab
Mortality at Day 1400
SecondaryTime to Return to Normal Activity

Time to return to normal activity from initiation of study treatment defined as duration from date of first exposure to treatment to the first occurrence of ordinal scale equals "not hospitalized, no limitations of activities"

Time frame:
Date of first exposure to treatment to the first occurrence of ordinal scale equals "not hospitalized, no limitations of activities"
Reported as:
Number · days
Time to Return to Normal Activity
daysPlacebo700mg Leronlimab
25th percentile pts return to normal4.05.0
50th percentile pts return to normal8.08.0
75th percentile pts return to normal9.015.0
SecondaryChange From Baseline in National Early Warning Score 2 (NEWS2) to Day 3, 7 and 14

NEWS2 is an assessment based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness) developed by the Royal College of Physicians (https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2). Respiratory rate (bpm) scores 0-3; Sp02 (on room air or suppl) scores 0-3; SpO2 (hypercapnic resp failure) scores 0-3; room air or supplemental O2 scores 0 (room) or 2 (suppl); temperature - scores 0-3; systolic BP scores 0-3; pulse (bpm) scores 0-3; consciousness - alert (score 0) vs. new onset confusion (score 3). The total possible score ranges from 0 to 20. The higher the score the greater the clinical risk. Higher scores indicate the need for escalation, medical review and possible clinical intervention and more intensive monitoring. Change shown is positive or negative from baseline, with a negative number indicating improvement (i.e., a decrease in total score).

Time frame:
Baseline to Day 3, 7 and 14
Reported as:
Mean · score on a scale
Change From Baseline in National Early Warning Score 2 (NEWS2) to Day 3, 7 and 14
score on a scalePlacebo700mg Leronlimab
Change from Baseline to Day 30.0 ± 0.87-0.3 ± 1.67
Change from Baseline to Day 7-0.2 ± 1.27-0.3 ± 2.24
Change from Baseline to Day 14-0.2 ± 1.06-0.4 ± 2.42
SecondaryMean Change in Percent Oxygen Saturation From Baseline to Days 3, 7 and 14

Mean change in percent oxygen saturation from baseline to Days 3, 7 and 14 for patients with paired values

Time frame:
Mean change in percent oxygen saturation from baseline to Days 3, 7 and 14
Reported as:
Mean · Mean change in % O2 sat
Mean Change in Percent Oxygen Saturation From Baseline to Days 3, 7 and 14
Mean change in % O2 satPlacebo700mg Leronlimab
Mean change from Baseline to Day 3 of percent oxygen saturation0.3 ± 1.91-0.1 ± 2.0
Mean change from Baseline to Day 7 of percent oxygen saturation0.4 ± 2.080.00 ± 2.30
Mean change from Baseline to Day 14 of percent oxygen saturation0.6 ± 1.730.3 ± 2.39
SecondaryChange From Baseline in the Patient's Health Status on a 7-category Ordinal Scale on Days 3, 7 and 14

A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Lower scores mean a worse outcome.

Time frame:
Assessments performed Day 0 (first treatment is Visit 2, day 0), Visit 3 (3+/- 1 day after first treatment) Visit 4 (second treatment, 7+/- 1 day from V2, day7) and end of treatment (7+/- 1 day from V4, day 14)
Reported as:
Mean · units on a scale
Change From Baseline in the Patient's Health Status on a 7-category Ordinal Scale on Days 3, 7 and 14
units on a scalePlacebo700mg Leronlimab
Mean change from baseline at day 30.4 ± 0.800.5 ± 0.75
Mean change from baseline at day 71.1 ± 0.780.7 ± 0.99
Mean change from baseline at day 141.2 ± 0.751.0 ± 1.13
Other pre-specifiedChange in Size of Lesion Area by Chest Radiograph or CT

Change in size of lesion area by chest radiograph or CT - exploratory endpoint

Time frame:
Day 14

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Serum Cytokine and Chemokine Levels

Change from baseline in serum cytokine and chemokine levels at day 3, day 7 and day 14

Time frame:
Days 3, 7, and 14

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in CCR5 Receptor Occupancy Levels for Tregs and Macrophages

Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages at day3, day 7 and day 14

Time frame:
Days 3, 7, and 14

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in CD3+, CD4+ and CD8+ T Cell Count

Change from baseline in CD3+, CD4+ and CD8+ T cell count at day 3, day 7 and day 14

Time frame:
Days 3, 7, and 14

Results for this outcome have not been posted.

Adverse events

Collected over Study drug was administered at Visit 2 (day 0) and visit 4 (day 7). Adverse events were assessed during the course of treatment and during the follow up period i.e., 2 weeks (visit 6) and 4 weeks (visit 7) after end of treatment. Therefore adverse events were assessed over a period of 5 weeks (visit 2 to visit 7).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/28 (0%)6/28 (21.4%)12/28 (42.9%)
700mg Leronlimab1/56 (1.8%)5/56 (8.9%)7/56 (12.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlacebo700mg Leronlimab
Chest PainGeneral disorders2/280/56
Atrial FibrillationCardiac disorders1/280/56
Mitral Valve IncompetenceCardiac disorders1/280/56
Abdominal PainGastrointestinal disorders1/280/56
Swelling faceGeneral disorders1/280/56
DehydrationMetabolism and nutrition disorders1/280/56
HypoaesthesiaNervous system disorders1/280/56
respiratory distressRespiratory, thoracic and mediastinal disorders1/280/56
HypotensionVascular disorders1/280/56
DeathGeneral disorders0/281/56
Most frequent other events
Most frequent other events
EventPlacebo700mg Leronlimab
Muscular weaknessMusculoskeletal and connective tissue disorders4/280/56
FatigueGeneral disorders2/281/56
PneumoniaInfections and infestations2/280/56
DiarrhoeaGastrointestinal disorders2/280/56
C-reactive protein increasedInvestigations1/283/56
Urinary Tract InfectionInfections and infestations1/283/56

Baseline characteristics

The Modified Intent-to-Treat (mITT) population is defined as the set of subjects who have received at least one dose of leronlimab or placebo and is population used for the analysis of efficacy parameters or measurements. The Safety Population includes all subjects who received at least one dose of leronlimab or placebo. This population was used for the analysis of safety parameters or measurements. There were 84 subjects in the MITT and Safety Population.

Age, Categorical
Age, Categorical(Participants)Placebo700mg LeronlimabTotal
<=18 years000
Between 18 and 65 years214263
>=65 years71421
Age, Continuous
Age, Continuous(years)Placebo700mg LeronlimabTotal
Mean55.36 (23 to 84)54.59 (30 to 79)54.85 (23 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo700mg LeronlimabTotal
Female193251
Male92433
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo700mg LeronlimabTotal
Hispanic or Latino101828
Not Hispanic or Latino173552
Unknown or Not Reported134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo700mg LeronlimabTotal
Hispanic or Latino101828
Not Hispanic or Latino173552
Unknown or Not Reported134
Region of Enrollment
Region of Enrollment(participants)Placebo700mg LeronlimabTotal
United States285684
COVID SYMPTOMS SCORE
COVID SYMPTOMS SCORE(Participants)Placebo700mg LeronlimabTotal
Baseline symptom score less than or equal to 4162945
Baseline symptom score greater than 4122739
08

Study locations

12 sites
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Palmtree Clinical Research, Inc.
    Palm Springs, California 92262-4871, United States
  • Eisenhower Health
    Rancho Mirage, California 92270, United States
  • Yale
    New Haven, Connecticut 06510, United States
  • Center for Advanced Research & Education (CARE)
    Gainesville, Georgia 30501, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Atlantic Health System Hospital
    Morristown, New Jersey 07962-1905, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • White Plains Hospital
    White Plains, New York 10601, United States
  • Novant Health
    Charlotte, North Carolina 27103, United States
  • Ohio Health
    Columbus, Ohio 43215, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Jul 2020, 3 months.

Results were first posted in Jan 2023, 2 years 5 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2020
First posted
Apr 13, 2020
StartActual
Apr 1, 2020
Primary completionActual
Jul 21, 2020
CompletionActual
Sep 20, 2021
Results first posted
Jan 4, 2023
Last update
Jan 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04343651
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Apr 13, 2020
Start date
Apr 1, 2020
Primary completion
Jul 21, 2020
Completion
Sep 20, 2021
Results posted
Jan 4, 2023
Last update
Jan 4, 2023

Study contacts

Angela Ritter, MD
principal investigator · Center for Advanced Research and Education

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion